Changes in Liver Fibrosis at the End of Interferon Therapy

Abstract: Background/Aims: The aims of the study were to determine, in patients with chronic hepatitis C treated with alpha interferon: (i) changes in the morphometric evaluation of liver fibrosis at the end of treatment and 6, 12 and 18 months after treatment; (ii) the predictive value of histologic lesions for the response to treatment, in particular the predictive value of morphometric evaluation of liver fibrosis.

Methods: Seventy patients with chronic hepatitis C who participated in two trials of recombinant interferon alpha 2b treatment mere studied. Liver specimens mere obtained before and at the end of treatment and 6, 12 or 18 months later. Histologic lesions mere assessed according to the Knodell system. Quantitative study of total fibrosis and of Disse space collagen was done by the computerized automated morphometric method.

Results: A significant decrease in morphometric Disse space collagen was observed at the end of treatment and 6 months later. This decrease was also observed, although it mas not significant, 12 and 18 months after treatment. There was no relationship between this decrease and the biochemical and virological responses or the dose of interferon. The pretreatment Knodell activity score, but not the morphometric evaluation of fibrosis, was a significant predictor of sustained response.

Conclusion: A decrease in Disse space collagen, as assessed by the sensitive morphometric method, was observed at the end of and 6 months after treatment. This observation is consistent with an anti-fibrogenetic effect of alpha interferon. Mild or moderate histologic activity was associated with a sustained response to therapy.

TITLE: Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method;
AUTHOR: Duchatelle V, Marcellin P, Giostra E, Bregeaud L, Pouteau M, Boyer N, Auperin A, Guerret S, Erlinger S, Henin D, Degott C;
SOURCE: JOURNAL OF HEPATOLOGY 29: (1) 20-28 JUL 1998

Also read:

• Interferon May Reverse Fibrosis In Some Patients
• What is Fibrosis?Area of Fibrosis Predictive of HCV Course
• Serum Hyaluronic Acid is a Useful Marker of Liver Fibrosis in Chronic HCV Infection

Triple Therapy Reduces Hepatitis C Drug Resistance
A review in the February 2010 issue of Gastroenterology sites viral resistance against new medications as incentive for using triple therapy to treat Hepatitis C.

Three HCV Drug Candidates Proceed to Phase II
Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.

Should Those with HCV Be Concerned About Bathing?
Find out how some with Hepatitis C unintentionally expose their skin to bath water contaminants that can place an additional burden on their liver.